PL2366405T3 - Przeciwciała antagonistyczne interleukiny IL-17 - Google Patents

Przeciwciała antagonistyczne interleukiny IL-17

Info

Publication number
PL2366405T3
PL2366405T3 PL10174725T PL10174725T PL2366405T3 PL 2366405 T3 PL2366405 T3 PL 2366405T3 PL 10174725 T PL10174725 T PL 10174725T PL 10174725 T PL10174725 T PL 10174725T PL 2366405 T3 PL2366405 T3 PL 2366405T3
Authority
PL
Poland
Prior art keywords
interleukin
antagonist antibodies
antagonist
antibodies
Prior art date
Application number
PL10174725T
Other languages
English (en)
Polish (pl)
Inventor
Padova Franco E Di
Hermann Gram
Hans Hofstetter
Margit Jeschke
Jean-Michel Rondeau
Den Berg Wim Van
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32982602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2366405(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2366405T3 publication Critical patent/PL2366405T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL10174725T 2004-08-05 2005-08-04 Przeciwciała antagonistyczne interleukiny IL-17 PL2366405T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0417487.6A GB0417487D0 (en) 2004-08-05 2004-08-05 Organic compound
EP05770286.2A EP1776142B9 (en) 2004-08-05 2005-08-04 Il-17 antagonistic antibodies
EP10174725.1A EP2366405B1 (en) 2004-08-05 2005-08-04 IL-17 antagonistic antibodies

Publications (1)

Publication Number Publication Date
PL2366405T3 true PL2366405T3 (pl) 2015-08-31

Family

ID=32982602

Family Applications (4)

Application Number Title Priority Date Filing Date
PL10174725T PL2366405T3 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne interleukiny IL-17
PL10175150T PL2364729T6 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne IL-17
PL15156029T PL2902039T3 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne wobec IL-17
PL05770286T PL1776142T4 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne wobec IL-17

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL10175150T PL2364729T6 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne IL-17
PL15156029T PL2902039T3 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne wobec IL-17
PL05770286T PL1776142T4 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne wobec IL-17

Country Status (40)

Country Link
US (9) US7807155B2 (enEXAMPLES)
EP (5) EP2902039B1 (enEXAMPLES)
JP (1) JP4682200B2 (enEXAMPLES)
KR (2) KR100852523B1 (enEXAMPLES)
CN (1) CN101001645B (enEXAMPLES)
AR (1) AR050200A1 (enEXAMPLES)
AT (1) ATE517924T1 (enEXAMPLES)
AU (2) AU2005268857C1 (enEXAMPLES)
BE (1) BE2015C041I2 (enEXAMPLES)
BR (3) BRPI0513078C1 (enEXAMPLES)
CA (1) CA2573586C (enEXAMPLES)
CY (6) CY1111963T1 (enEXAMPLES)
DK (4) DK2902039T3 (enEXAMPLES)
EC (1) ECSP077198A (enEXAMPLES)
ES (4) ES2367440T7 (enEXAMPLES)
FR (1) FR15C0048I2 (enEXAMPLES)
GB (1) GB0417487D0 (enEXAMPLES)
HK (1) HK1256639A1 (enEXAMPLES)
HR (3) HRP20110758T4 (enEXAMPLES)
HU (4) HUE025815T2 (enEXAMPLES)
IL (1) IL180717A (enEXAMPLES)
LT (3) LT2902039T (enEXAMPLES)
LU (2) LU92768I2 (enEXAMPLES)
MA (1) MA28982B1 (enEXAMPLES)
MX (1) MX2007001338A (enEXAMPLES)
MY (1) MY144925A (enEXAMPLES)
NL (1) NL300749I2 (enEXAMPLES)
NO (9) NO336279B1 (enEXAMPLES)
NZ (1) NZ552658A (enEXAMPLES)
PE (1) PE20060418A1 (enEXAMPLES)
PL (4) PL2366405T3 (enEXAMPLES)
PT (4) PT2902039T (enEXAMPLES)
RU (2) RU2426741C3 (enEXAMPLES)
SG (1) SG155186A1 (enEXAMPLES)
SI (4) SI2364729T1 (enEXAMPLES)
TN (1) TNSN07034A1 (enEXAMPLES)
TR (1) TR201808057T4 (enEXAMPLES)
TW (1) TWI359153B (enEXAMPLES)
WO (1) WO2006013107A1 (enEXAMPLES)
ZA (1) ZA200700242B (enEXAMPLES)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
PL1933869T3 (pl) * 2005-09-01 2010-06-30 Merck Sharp & Dohme Zastosowanie antagonistów IL-23 i IL-17 do leczenia autoimmunologicznej zapalnej choroby oczu
ES2389780T7 (es) * 2005-12-13 2021-01-14 Lilly Co Eli Anticuerpos anti-IL-17
UA97946C2 (ru) 2005-12-20 2012-04-10 Эс-Би-Ай Биотех Ко., Лтд. Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
BRPI0706788A2 (pt) 2006-01-31 2011-04-05 Novartis Ag anticorpos antagonistas il-17
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
EP2044118A2 (en) 2006-06-13 2009-04-08 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
CN101646690B (zh) * 2006-08-11 2013-10-23 默沙东公司 抗il-17a抗体
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
MX2009009167A (es) 2007-02-28 2009-09-04 Schering Corp Terapia de combinacion para el tratamiento de trastornos inmunes.
KR20180032687A (ko) 2007-05-29 2018-03-30 노파르티스 아게 항-ｉｌ-1-베타 치료법에 대한 신규 적응증
US20100239590A1 (en) * 2007-06-20 2010-09-23 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
EP2182943B1 (en) * 2007-07-23 2016-10-26 Janssen Biotech, Inc. Methods and compositions for treating fibrosis related disorders using il-17 antagonists
US20110195509A1 (en) * 2007-09-06 2011-08-11 Drew Pardoll Treatment of th17-mediated autoimmune disease via inhibition of stat 3
KR101616995B1 (ko) * 2007-12-03 2016-06-07 (주)아모레퍼시픽 슬리밍용 조성물
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CA2711696C (en) 2008-01-09 2021-10-26 Reza Dana Therapeutic compositions for treatment of ocular inflammatory disorders
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
CN102014958A (zh) * 2008-04-29 2011-04-13 米克罗麦特股份公司 用于治疗的gm-csf和il-17抑制剂
MX2010011955A (es) 2008-04-29 2011-01-21 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
CA2721713C (en) 2008-05-05 2019-07-09 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
CN102112495A (zh) 2008-06-03 2011-06-29 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
CA2725666A1 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
SG192489A1 (en) 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
NZ591484A (en) 2008-09-29 2012-09-28 Roche Glycart Ag Antibodies against human il 17 and uses thereof
TW201613969A (en) 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
CN104725512A (zh) * 2009-04-27 2015-06-24 诺华股份有限公司 增加肌肉生长的组合物和方法
EP2427203B1 (en) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f antibodies and use thereof
JP2013503607A (ja) 2009-09-01 2013-02-04 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
WO2011044563A2 (en) * 2009-10-10 2011-04-14 The Board Of Trustees Of The Leland Stanford Junior University Il-17 family cytokine compositions and uses
CN102666875A (zh) 2009-10-15 2012-09-12 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
NZ599737A (en) 2009-10-30 2015-02-27 Janssen Biotech Inc Il-17a antagonists
WO2011144749A1 (en) 2010-05-20 2011-11-24 Ablynx Nv Biological materials related to her3
AU2011285852B2 (en) 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP2013537414A (ja) * 2010-08-05 2013-10-03 アナプティスバイオ インコーポレイティッド Ｉｌ−１７に対する抗体
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
AU2011311482B2 (en) * 2010-10-08 2014-05-29 Novartis Ag Methods of treating psoriasis using IL-17 antagonists
AU2014259523B2 (en) * 2010-11-05 2016-02-04 Novartis Ag Methods of treating psoriatic arthritis using IL-17 antagonists
CA2813849C (en) * 2010-11-05 2021-06-15 Novartis Ag Secukinumab for use in the treatment of ankylosing spondylitis
TW201307845A (zh) 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
JP5947041B2 (ja) * 2011-01-07 2016-07-06 第一三共ヘルスケア株式会社 安全なｉｌ−１７産生抑制剤
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US20140004540A1 (en) * 2011-01-13 2014-01-02 Universite Paris Descartes Methods and kits for predicting the risk of having a cardiovascular event in a subject
EP2663577B1 (en) 2011-01-14 2017-04-12 UCB Biopharma SPRL Antibody binding il-17a and il-17f
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
KR102058254B1 (ko) * 2011-03-29 2019-12-20 글락소스미스클라인 엘엘씨 단백질 정제용 완충제 시스템
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013052523A1 (en) 2011-10-03 2013-04-11 modeRNA Therapeutics Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CN104011223A (zh) * 2011-11-21 2014-08-27 诺华股份有限公司 使用il-17拮抗剂及psa应答或非应答等位基因治疗银屑病性关节炎(psa)的方法
WO2013082282A1 (en) 2011-12-02 2013-06-06 lNOVARTIS AG Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease.
WO2013087913A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243953A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2868404A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
CA2870025A1 (en) 2012-04-20 2013-10-24 Novartis Ag Methods of treating ankylosing spondylitis using il-17 antagonists
WO2013177101A2 (en) 2012-05-22 2013-11-28 Bristol-Myers Squibb Company Bispecific antibodies and methods of using the same
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
KR20190096459A (ko) 2012-11-01 2019-08-19 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
WO2014107737A2 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
MA38322B1 (fr) 2013-02-08 2018-09-28 Novartis Ag Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
EP3033107A1 (en) * 2013-08-15 2016-06-22 Novartis AG Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
KR20240090993A (ko) 2013-08-30 2024-06-21 다케다 야쿠힌 고교 가부시키가이샤 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
EP3072905B1 (en) * 2013-11-18 2020-08-19 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-17a binding agent and uses thereof
US20160340422A1 (en) * 2014-01-28 2016-11-24 Beijing Hanmi Pharmaceutical Co., Ltd. Bifunctional fusion protein, preparation method therefor, and use thereof
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
JP2017528465A (ja) 2014-09-10 2017-09-28 ノバルティス アーゲー 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ−１７アンタゴニストの使用
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
PE20171067A1 (es) 2014-10-14 2017-07-24 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
KR20240110106A (ko) 2015-01-12 2024-07-12 애피바디 에이비 Il-17a-결합 폴리펩티드
JP2018506275A (ja) 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
CN108251431B (zh) 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP2018521047A (ja) 2015-07-16 2018-08-02 イーライ リリー アンド カンパニー 掻痒の治療
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US20190330328A1 (en) 2015-10-19 2019-10-31 Christian Mann Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
KR102833068B1 (ko) 2015-12-17 2025-07-14 노파르티스 아게 Pd-1에 대한 항체 분자 및 그의 용도
IL321334A (en) 2016-03-10 2025-08-01 Viela Bio Inc ILT7 binding molecules and methods of using them
EP3426680B1 (en) 2016-03-10 2024-08-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
FR3051673B1 (fr) * 2016-05-24 2018-06-22 Assistance Publique - Hopitaux De Paris Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
ES2992409T3 (es) 2016-07-19 2024-12-12 Novartis Ag Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17
ES2905917T3 (es) 2016-09-14 2022-04-12 Beijing Hanmi Pharmaceutical Co Ltd Anticuerpo que se une específicamente a IL-17A y fragmento funcional del mismo
WO2018096467A1 (en) 2016-11-28 2018-05-31 Novartis Ag Methods of treating acne using interleukin-17 (il-17) antagonists
SG11201907364WA (en) 2017-02-10 2019-09-27 Genentech Inc Anti-tryptase antibodies, compositions thereof, and uses thereof
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
TW201842933A (zh) 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
CN108359011B (zh) 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
US20210179702A1 (en) 2017-11-02 2021-06-17 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17)
US20200277369A1 (en) * 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
JP2021509009A (ja) 2017-11-30 2021-03-18 ノバルティス アーゲー Ｂｃｍａターゲティングキメラ抗原受容体及びその使用
JP2021519589A (ja) * 2018-03-29 2021-08-12 アールイーエムディー バイオセラピューティクス，インコーポレイテッドＲＥＭＤ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ インターロイキン１７ａ（ｉｌ−１７ａ）に結合する抗体を用いた自己免疫障害及び炎症障害の治療
MA52785A (fr) 2018-06-01 2021-04-14 Novartis Ag Molécules de liaison dirigées contre bcma et leurs utilisations
WO2020024931A1 (en) * 2018-07-31 2020-02-06 Shen Weiqun Anti-il-17a antibodies and use thereof
EP3856772A1 (en) 2018-09-25 2021-08-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
WO2020157305A1 (en) 2019-01-31 2020-08-06 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
CN113474360B (zh) 2019-02-18 2025-01-07 伊莱利利公司 治疗性抗体制剂
CN110179746A (zh) 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
CA3142267A1 (en) 2019-05-31 2020-12-03 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
KR102815628B1 (ko) 2019-07-26 2025-06-02 사이노셀테크 엘티디. 인간화 항-il17a 항체 및 이의 용도
US20220267432A1 (en) 2019-07-30 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Method for treating autoimmune disease by il-17 antagonist
KR20220066318A (ko) 2019-09-20 2022-05-24 노파르티스 아게 인터류킨-17(il-17) 길항제를 사용한 자가면역 질환의 치료 방법
CN114423455A (zh) * 2019-09-25 2022-04-29 国立大学法人东京大学 用于治疗系统性硬化症的药物组合物
EP4042167B1 (en) 2019-09-30 2025-04-09 Janssen Pharmaceutica NV Compositions and methods for an il-17 target engagement assay with large molecule modulators
AU2020386669A1 (en) 2019-11-19 2022-06-02 Novartis Ag Methods of treating Lupus Nephritis using interleukin-17 (IL-17) antagonists
KR20220110512A (ko) 2019-12-06 2022-08-08 노파르티스 아게 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법
CN114805577B (zh) * 2019-12-31 2023-11-21 南京融捷康生物科技有限公司 针对il-17ra蛋白的抗体及其制备方法和应用
AU2021296436A1 (en) 2020-06-23 2023-02-02 Novartis Ag Methods of treating Thyroid Eye Disease and Graves' Orbitopahy using Interleukin-17 (IL-17) antagonists
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
CA3199095A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
EP4255927A1 (en) 2020-12-02 2023-10-11 Fresenius Kabi Deutschland GmbH Methods of selectively reducing antibodies
US20220251502A1 (en) 2020-12-22 2022-08-11 Novartis Ag Methods for reducing the oxidation level of cysteine residues in a secreted recombinantly-expressed protein during cell culture
US20250276957A1 (en) 2022-04-25 2025-09-04 Novartis Ag Crystalline forms of an il-17 inhibitor
WO2023223211A1 (en) 2022-05-16 2023-11-23 Novartis Ag Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
JP2025516723A (ja) 2022-05-18 2025-05-30 ノバルティス アーゲー インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を選択的に治療する方法
WO2024156841A1 (en) 2023-01-27 2024-08-02 Fresenius Kabi Deutschland Gmbh Biopharmaceutical composition
EP4406553A1 (en) 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
CN117843778B (zh) * 2023-12-21 2024-07-26 北京贝来药业有限公司 针对白介素家族成员的新型纳米抗体及其产品和应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
PT817847E (pt) 1995-03-23 2005-02-28 Immunex Corp Receptor de il-17
DE69634726T2 (de) * 1995-07-19 2006-05-04 Genetics Institute, LLC, Cambridge Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
JP3253633B2 (ja) 1995-10-27 2002-02-04 シェーリング コーポレイション 哺乳動物ｃｔｌａ−８および関連薬剤の新規使用
ES2326347T3 (es) 1996-11-27 2009-10-07 Immunex Corporation Metodo para regular la produccion de oxido nitrico.
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
ES2333385T3 (es) 1997-09-17 2010-02-19 Human Genome Sciences, Inc. Proteina del tipo de interleuquina-17.
NZ504291A (en) 1997-11-10 2002-10-25 Cytimmune Sciences Inc Compositions and methods for targeted delivery of factors
US6562578B1 (en) 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
WO1999032632A1 (en) 1997-12-19 1999-07-01 Millennium Pharmaceuticals, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
JP2003502006A (ja) 1998-01-09 2003-01-21 イミュネックス・コーポレーション Ｉｌ−１７ｒｈｄｎａ及びポリペプチド
WO1999035267A1 (en) 1998-01-09 1999-07-15 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
CA2320431A1 (en) 1998-02-11 1999-08-19 Maxygen, Inc. Targeting of genetic vaccine vectors
IL138930A0 (en) 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
AU6050499A (en) 1998-09-17 2000-04-03 Zymogenetics Inc. Mammalian transforming growth factor beta - 9 (ztgfss9)
WO2000020593A1 (en) 1998-10-02 2000-04-13 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and uses thereof
JP2000186046A (ja) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
AU1071200A (en) 1998-10-19 2000-05-08 Biotech Australia Pty Limited Systems for oral delivery
DE29820466U1 (de) 1998-11-16 1999-04-08 Reutter, Werner, Prof. Dr.med., 14195 Berlin Rekombinante Glycoproteine und sie enthaltende Arzneimittel
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
ES2333694T3 (es) 1999-01-11 2010-02-26 Schering Corporation Citoquinas de mamiferos relacionados con la interleuquina-17.polinucleotido que las codifican y sus instalaciones.
AU3207000A (en) 1999-01-11 2000-08-01 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
RU2236251C2 (ru) 1999-02-12 2004-09-20 Дзе Скриппс Рисерч Инститьют Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии
US6036128A (en) 1999-05-17 2000-03-14 Common Ground Recycling, Inc. Tire shredding machine and method of using the same
EP1053751A1 (en) 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
AU6677000A (en) 1999-08-27 2001-03-26 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
JP2001086046A (ja) * 1999-09-09 2001-03-30 Nec Corp カメラ付き携帯電話装置
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
DK1294769T3 (da) 2000-06-16 2011-04-26 Human Genome Sciences Inc Antistoffer der immunspecifikt binder til BLyS
ES2277947T3 (es) 2000-10-13 2007-08-01 Eli Lilly And Company Procedimientos de uso de un polipeptido afin a il-17 humana para tratar enfermedades.
JP2004517918A (ja) 2000-10-18 2004-06-17 イミュネックス・コーポレーション Ｉｌ−１７アンタゴニストを使用する慢性関節リューマチの治療法
DE60239450D1 (de) 2001-01-25 2011-04-28 Zymogenetics Inc Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
EP2009027B1 (en) * 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
CA2467521A1 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
CA2496795C (en) 2002-08-28 2014-06-03 Paul B. Burton Compositions and methods for treating cardiovascular disease
US7456264B2 (en) * 2003-05-21 2008-11-25 Medarex, Inc. Human monoclonal antibodies against Bacillus anthracis protective antigen
PT1983000E (pt) 2003-11-21 2015-12-30 Ucb Biopharma Sprl Método para o tratamento de esclerose múltipla através da inibição da atividade de il-17
EP1761643A1 (en) * 2004-05-03 2007-03-14 Schering Corporation Use of il-17 expression to predict skin inflammation; methods of treatment
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
PL1933869T3 (pl) * 2005-09-01 2010-06-30 Merck Sharp & Dohme Zastosowanie antagonistów IL-23 i IL-17 do leczenia autoimmunologicznej zapalnej choroby oczu

Also Published As

Publication number Publication date
CY2015030I1 (el) 2015-11-04
LTPA2015029I1 (lt) 2022-07-11
AU2010201689B2 (en) 2011-09-29
EP1776142B1 (en) 2011-07-27
AU2005268857A1 (en) 2006-02-09
MY144925A (en) 2011-11-30
BRPI0513078B1 (pt) 2019-02-19
AR050200A1 (es) 2006-10-04
HRP20181069T1 (hr) 2018-09-07
DK2366405T3 (en) 2015-05-11
ATE517924T1 (de) 2011-08-15
CY1111963T1 (el) 2015-11-04
PL1776142T6 (pl) 2016-06-30
EP2364729B1 (en) 2014-05-14
SI1776142T1 (sl) 2011-11-30
NO336279B1 (no) 2015-07-06
NL300749I2 (nl) 2017-11-02
ES2367440T9 (es) 2021-04-28
CA2573586C (en) 2013-06-25
EP2366405B1 (en) 2015-02-25
EP3409288A1 (en) 2018-12-05
CA2573586A1 (en) 2006-02-09
NO337129B1 (no) 2016-01-25
HRP20150480T1 (hr) 2015-07-17
US7807155B2 (en) 2010-10-05
LTC1776142I2 (lt) 2022-07-11
KR20070036166A (ko) 2007-04-02
NO2015023I1 (no) 2015-11-02
PL2364729T3 (pl) 2014-10-31
KR20080029018A (ko) 2008-04-02
FR15C0048I1 (fr) 2015-08-28
US20150152178A1 (en) 2015-06-04
US20190270804A1 (en) 2019-09-05
NO348010B1 (no) 2024-06-17
ZA200700242B (en) 2008-08-27
EP2364729A2 (en) 2011-09-14
KR100852523B1 (ko) 2008-08-14
PL1776142T3 (pl) 2011-12-30
PT2364729E (pt) 2014-09-01
EP2364729A3 (en) 2012-01-18
NO20150064L (no) 2007-03-30
TW200617025A (en) 2006-06-01
BR122017009404B1 (pt) 2022-02-22
RU2011113153A (ru) 2012-10-20
RU2426741C2 (ru) 2011-08-20
AU2005268857C1 (en) 2012-01-19
JP4682200B2 (ja) 2011-05-11
BRPI0513078C1 (pt) 2021-05-25
AU2010201689A1 (en) 2010-05-20
LTPA2018515I1 (lt) 2018-10-25
NO2016017I1 (no) 2016-08-23
GB0417487D0 (en) 2004-09-08
MX2007001338A (es) 2008-03-11
TNSN07034A1 (en) 2008-06-02
NZ552658A (en) 2009-11-27
DK1776142T3 (da) 2011-10-31
HK1207559A1 (en) 2016-02-05
US8617552B2 (en) 2013-12-31
HK1101277A1 (en) 2007-10-12
HK1256639A1 (en) 2019-09-27
CY1120723T1 (el) 2019-12-11
HUS1800040I1 (hu) 2018-11-28
SI2366405T1 (sl) 2015-07-31
DK2364729T6 (en) 2015-07-06
NO2022026I1 (no) 2022-06-24
RU2007108067A (ru) 2008-09-10
US8119131B2 (en) 2012-02-21
EP2364729B3 (en) 2015-06-24
RU2426741C3 (ru) 2017-11-15
ES2487533T3 (es) 2014-08-21
CN101001645B (zh) 2012-09-05
PT2902039T (pt) 2018-07-17
EP2902039A1 (en) 2015-08-05
US20100215666A1 (en) 2010-08-26
NO20150065L (no) 2007-03-30
ES2536228T3 (es) 2015-05-21
BRPI0513078A (pt) 2008-04-22
ES2367440T3 (es) 2011-11-03
WO2006013107A1 (en) 2006-02-09
ECSP077198A (es) 2007-02-28
NO20070985L (no) 2007-03-30
EP2366405A2 (en) 2011-09-21
US20120107325A1 (en) 2012-05-03
CY2018027I2 (el) 2020-05-29
AU2005268857B8 (en) 2010-05-27
AU2005268857B2 (en) 2010-01-28
DK2364729T3 (da) 2014-07-21
PL1776142T4 (pl) 2018-04-30
DK1776142T6 (en) 2015-07-06
KR100852523B9 (ko) 2025-03-28
HUE025815T2 (en) 2016-04-28
PT1776142E (pt) 2011-10-06
JP2008507988A (ja) 2008-03-21
CY1115444T1 (el) 2017-01-04
NO2018007I1 (no) 2018-02-14
BE2015C041I2 (enEXAMPLES) 2024-10-08
TR201808057T4 (tr) 2018-06-21
NO337286B1 (no) 2016-02-29
US20230235038A1 (en) 2023-07-27
NO20151787L (no) 2006-02-06
DK2902039T3 (en) 2018-07-16
PT2366405E (pt) 2015-06-30
BRPI0513078B8 (pt) 2019-08-27
MA28982B1 (fr) 2007-11-01
HRP20110758T1 (en) 2011-11-30
US20090280131A1 (en) 2009-11-12
SI2902039T1 (en) 2018-07-31
CN101001645A (zh) 2007-07-18
EP1776142A1 (en) 2007-04-25
HUS1500037I1 (hu) 2017-10-30
CY2015030I2 (el) 2017-11-14
PL2902039T3 (pl) 2018-09-28
HRP20110758T4 (hr) 2015-07-31
US10344084B2 (en) 2019-07-09
EP1776142B3 (en) 2015-06-24
ES2367440T7 (es) 2015-07-14
US20170355762A1 (en) 2017-12-14
US20140079719A1 (en) 2014-03-20
LU92768I2 (fr) 2015-11-03
LUC00088I2 (enEXAMPLES) 2018-12-17
NO20171697A1 (no) 2007-03-30
ES2487533T7 (es) 2015-07-14
TWI359153B (en) 2012-03-01
NO2015023I2 (no) 2015-10-26
PL2364729T6 (pl) 2016-06-30
US20250122277A1 (en) 2025-04-17
EP2902039B1 (en) 2018-04-11
SG155186A1 (en) 2009-09-30
ES2677245T3 (es) 2018-07-31
US9765140B2 (en) 2017-09-19
LT2902039T (lt) 2018-06-25
IL180717A0 (en) 2007-06-03
CY2018027I1 (el) 2020-05-29
CY1116256T1 (el) 2017-02-08
EP2366405A3 (en) 2012-01-18
IL180717A (en) 2012-07-31
HUE038187T2 (hu) 2018-10-29
FR15C0048I2 (fr) 2015-11-20
NO341384B1 (no) 2017-10-30
BR122018075556B1 (pt) 2022-10-18
SI2364729T1 (sl) 2014-08-29
PE20060418A1 (es) 2006-06-15
EP1776142B9 (en) 2016-09-07

Similar Documents

Publication Publication Date Title
PL2366405T3 (pl) Przeciwciała antagonistyczne interleukiny IL-17
HUS2100053I1 (hu) Interleukin-13-antitest-készítmény
CY2016030I2 (el) Αντισωματα εναντι της il-17
NO20071430L (no) Anti-OX4OL antistoffer
NO20071069L (no) Anti-CD154-antistoff
ATE501174T1 (de) Antikörper gegen madcam
DK1737891T3 (da) Anti-p-selectin-antistoffer
DK1771482T3 (da) HER2-antistofsammensætning
HRP20150176T1 (xx) Protutijela protiv miostatina
DK1964852T3 (da) Anti-ilt7-antistof
NO20076607L (no) TWEAK - bindende antistoff
DK1599504T3 (da) Modificeret antistof
ATE483732T1 (de) Madcam-antikörper
CY2013046I1 (el) Καινοτομος χρηση των αντισωματων αντι il-1bhta
EP1765396A4 (en) ANTIBODY
DK1809660T3 (da) Thymus-specifikt protein
BRPI0509495A2 (pt) anticorpo humanizado
EP1712564A4 (en) MONOCLONAL ANTI-NC1 ANTIBODY
IS8562A (is) Ónæmisglóbúlín